LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03287947
Recruitment Status : Recruiting
First Posted : September 19, 2017
Last Update Posted : August 28, 2018
Boehringer Ingelheim
Information provided by (Responsible Party):
Jimmy Hwang, Carolinas Healthcare System

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : September 1, 2021
  Estimated Study Completion Date : March 1, 2022